Baseline characteristics of patients used in match adjustment in epcoritamab (expansion and optimization cohorts) vs odronextamab cohort
| Characteristic . | Efficacy comparison (expansion cohort) . | Safety comparison (optimization cohort) . | Odronextamab cohort, % (n = 128) . | ||
|---|---|---|---|---|---|
| Unadjusted epcoritamab cohort, % (n = 122) . | Adjusted epcoritamab cohort, % (ESS = 40) . | Unadjusted epcoritamab cohort, % (n = 80) . | Adjusted epcoritamab cohort, % (ESS = 30) . | ||
| Age ≥65 years | 53.3 | 37.2 | 41.3 | 37.2 | 37.2 |
| Age ≥75 years | 13.1 | 9.4 | 12.5 | 9.4 | 9.4 |
| Male | 61.5 | 53.1 | 56.3 | 53.1 | 53.1 |
| ECOG PS of 0 (vs 1-2) | 54.9 | 50.8 | 62.5 | 50.8 | 50.8 |
| Disease stage III-IV | 84.4 | 85.2 | 91.3 | 85.2 | 85.2 |
| FLIPI score of ≥3 | 60.7 | 57.8 | 51.3 | 57.8 | 57.8 |
| Prior ASCT | 19.7 | 30.5 | 23.8 | 30.5 | 30.5 |
| POD24 | 50.8 | 49.2 | 50.0 | 49.2 | 49.2 |
| Refractory to any prior anti-CD20 | 77.9 | 74.2 | 76.3 | 74.2 | 74.2 |
| Refractory to any prior anti-CD20 and alkylator therapy | 68.9 | 41.4 | 61.3 | 41.4 | 41.4 |
| Refractory to last prior therapy | 68.9 | 71.9 | 58.8 | 71.9 | 71.9 |
| Bulky disease (>7 cm for epcoritamab/unknown for odronextamab) | 12.3 | 14.1 | 12.5 | 14.1 | 14.1 |
| ≥3 prior LOTs | 61.5 | 53.9 | 43.8 | 53.9 | 53.9 |
| Prior R2 | 19.7 | 13.3 | 27.5 | 13.3 | 13.3 |
| Characteristic . | Efficacy comparison (expansion cohort) . | Safety comparison (optimization cohort) . | Odronextamab cohort, % (n = 128) . | ||
|---|---|---|---|---|---|
| Unadjusted epcoritamab cohort, % (n = 122) . | Adjusted epcoritamab cohort, % (ESS = 40) . | Unadjusted epcoritamab cohort, % (n = 80) . | Adjusted epcoritamab cohort, % (ESS = 30) . | ||
| Age ≥65 years | 53.3 | 37.2 | 41.3 | 37.2 | 37.2 |
| Age ≥75 years | 13.1 | 9.4 | 12.5 | 9.4 | 9.4 |
| Male | 61.5 | 53.1 | 56.3 | 53.1 | 53.1 |
| ECOG PS of 0 (vs 1-2) | 54.9 | 50.8 | 62.5 | 50.8 | 50.8 |
| Disease stage III-IV | 84.4 | 85.2 | 91.3 | 85.2 | 85.2 |
| FLIPI score of ≥3 | 60.7 | 57.8 | 51.3 | 57.8 | 57.8 |
| Prior ASCT | 19.7 | 30.5 | 23.8 | 30.5 | 30.5 |
| POD24 | 50.8 | 49.2 | 50.0 | 49.2 | 49.2 |
| Refractory to any prior anti-CD20 | 77.9 | 74.2 | 76.3 | 74.2 | 74.2 |
| Refractory to any prior anti-CD20 and alkylator therapy | 68.9 | 41.4 | 61.3 | 41.4 | 41.4 |
| Refractory to last prior therapy | 68.9 | 71.9 | 58.8 | 71.9 | 71.9 |
| Bulky disease (>7 cm for epcoritamab/unknown for odronextamab) | 12.3 | 14.1 | 12.5 | 14.1 | 14.1 |
| ≥3 prior LOTs | 61.5 | 53.9 | 43.8 | 53.9 | 53.9 |
| Prior R2 | 19.7 | 13.3 | 27.5 | 13.3 | 13.3 |